Showing results (41-50 of 245) with videos related to

Sort By:
Pageof 25
Proceedings of the National Academy of Sciences of the United States of America|March 31, 2022
Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathwayLaura A Stransky, Sean M Vigeant, Bofu Huang, et al.
Radiology|July 21, 2007
Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in miceAntoine Hakimé, Andrew Hines-Peralta, Himaja Peddi, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|August 18, 2011
Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal modelWei Yang, Muneeb Ahmed, Beenish Tasawwar, et al.
Radiology|April 29, 2005
Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animalsMuneeb Ahmed, Zhengjun Liu, Anatoly N Lukyanov, et al.
Oncotarget|May 5, 2016
Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse modelEloah Rabello Suarez, De Kuan Chang, Jiusong Sun, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2014
Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2αNils Kroeger, David B Seligson, Sabina Signoretti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancerMichael Atkins, Meredith Regan, David McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2010
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinomaDaniel C Cho, Matthew B Cohen, David J Panka, et al.
Science Signaling|October 3, 2019
HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across speciesHilary E Nicholson, Zeshan Tariq, Benjamin E Housden, et al.
Radiology|February 26, 2005
Reduced tumor growth with combined radiofrequency ablation and radiation therapy in a rat breast tumor modelClare Horkan, Kshitij Dalal, Jeffrey A Coderre, et al.
Pageof 25